Wall Street cheers Hong Kong’s IPO rules revamp but sees New York’s dominance unthreatened

Earlier this month, Shanghai Henlius Biotech Inc, a biotech company owned by Shanghai Fosun Pharmaceutical (Group) Co, also was reported to be planning a Hong Kong IPO. The offering, expected to occur in the second half of this year, could raise at least …
( read original story …)

Related Post